{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T07:54:11Z","timestamp":1772783651135,"version":"3.50.1"},"reference-count":87,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02264","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T11:46:06Z","timestamp":1538394366000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies"],"prefix":"10.3389","volume":"9","author":[{"given":"Uffe","family":"Klausen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Staffan","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Orebo","family":"Holmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolai Gr\u00f8nne Dahlager","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob Handlos","family":"Grauslund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge Marie","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mads Hald","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,1]]},"reference":[{"key":"B1","first-page":"154","article-title":"The toxins of William, B. Coley and the treatment of bone and soft-tissue sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"S185","DOI":"10.1016\/J.SEMCANCER.2015.03.004","article-title":"Immune evasion in cancer: mechanistic basis and therapeutic strategies","volume":"35","author":"Vinay","year":"2015","journal-title":"Semin Cancer Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma : a mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1007\/s00018-016-2135-z","article-title":"Immune responses in multiple myeloma: role of the natural immune surveillance and potential of immunotherapies","volume":"73","author":"Guillerey","year":"2016","journal-title":"Cell Mol Life Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2015-03-632919","article-title":"Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy","volume":"126","author":"Dhodapkar","year":"2015","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1182\/blood-2016-03-707547","article-title":"Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication","volume":"128","author":"An","year":"2016","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect : a therapeutic target for CT-011, a novel monoclonal anti \u2013 PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.bbmt.2011.03.011","article-title":"Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade","volume":"17","author":"Hallett","year":"2011","journal-title":"Biol Blood Marrow Transplant."},{"key":"B13","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-\u03b3 and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/leu.2015.11","article-title":"Targeting PD1\u2013PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells","volume":"29","author":"Ray","year":"2015","journal-title":"Leukemia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1158\/1078-0432.CCR-13-0282","article-title":"Vaccination with dendritic cell\/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients","volume":"19","author":"Rosenblatt","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139867","article-title":"PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy","author":"Sponaas","year":"2015","journal-title":"PLoS ONE"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/leu.2015.79","article-title":"PD-L1\/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1158\/2326-6066.CIR-15-0296","article-title":"Myeloma drug resistance induced by binding of myeloma B7-H1 (PD-L1) to PD-1","volume":"4","author":"Ishibashi","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.leukres.2016.09.008","article-title":"PD-1\/PD-L1 expression in extra-medullary lesions of multiple myeloma","volume":"49","author":"Crescenzi","year":"2016","journal-title":"Leuk Res."},{"key":"B20","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1182\/blood.V126.23.1785.1785","article-title":"Presence of PD-1 expressing T cells predicts for inferior overall survival in newly diagnosed multiple myeloma","volume":"126","author":"Gasmi","year":"2015","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/leu.2012.213","article-title":"Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma","volume":"27","author":"Tamura","year":"2013","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","article-title":"T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy","volume":"4","author":"Chung","year":"2016","journal-title":"Cancer Immunol Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1158\/0008-5472.CAN-12-3507","article-title":"HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients","volume":"73","author":"Munir","year":"2013","journal-title":"Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.4161\/onci.23991","article-title":"The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4(+) T cells","author":"Munir","year":"2013","journal-title":"Oncoimmunology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/leu.2013.261","article-title":"Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway","volume":"28","author":"Ahmad","year":"2014","journal-title":"Leukemia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.50","article-title":"The stimulation of PD-L1-specific cytotoxic T lymphocytes can both directly and indirectly enhance antileukemic immunity","author":"Ahmad","year":"","journal-title":"Blood Cancer J. ("},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1202391","DOI":"10.1080\/2162402X.2016.1202391","article-title":"PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine","volume":"5","author":"Munir","year":"2016","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"A291","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies","volume":"124","author":"Lesokhin","year":"2014","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/ajh.21560","article-title":"Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival","volume":"84","author":"Lacy","year":"2009","journal-title":"Am J Hematol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1200\/JCO.2012.43.9273","article-title":"Active idiotypic vaccination versus control immunotherapy for follicular lymphoma","volume":"32","author":"Levy","year":"2014","journal-title":"J Clin Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2010.33.3005","article-title":"Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma","volume":"29","author":"Schuster","year":"2011","journal-title":"J Clin Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1026530","article-title":"Several immune escape patterns in non-Hodgkin's lymphomas","author":"Laurent","year":"2015","journal-title":"Oncoimmunology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1182\/blood-2012-04-421826","article-title":"High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells","volume":"121","author":"Myklebust","year":"2013","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"4232","DOI":"10.1158\/1078-0432.CCR-10-2660","article-title":"Programmed death ligand 1 is expressed by non-Hodgkin lymphomas and inhibits the activity of tumor-associated T cells","volume":"17","author":"Andorsky","year":"2011","journal-title":"Clin Cancer Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1390641","DOI":"10.1080\/2162402X.2017.1390641","article-title":"The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy","volume":"7","author":"Ahmad","year":"2017","journal-title":"Oncoimmunology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.1182\/blood-2009-11-253260","article-title":"Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment","volume":"115","author":"Clear","year":"2010","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.3324\/haematol.2009.021766","article-title":"Vascularization predicts overall survival and risk of transformation in follicular lymphoma","volume":"95","author":"Farinha","year":"2010","journal-title":"Haematologica"},{"key":"B39","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/leu.2011.179","article-title":"Monocytes and T cells cooperate to favor normal and follicular lymphoma B-cell growth: role of IL-15 and CD40L signaling","volume":"26","author":"Epron","year":"2012","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/ijc.23607","article-title":"Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine","volume":"123","author":"Stresemann","year":"2008","journal-title":"Int J Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/08820139.2016.1197241","article-title":"Cancer\/Testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers","volume":"45","author":"Salmaninejad","year":"2016","journal-title":"Immunol Invest."},{"key":"B42","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","article-title":"The DNA demethylating agent 5-aza-2\u2032-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells","volume":"34","author":"Almstedt","year":"2010","journal-title":"Leuk Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","article-title":"Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia","volume":"116","author":"Goodyear","year":"2010","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e12994","DOI":"10.1371\/journal.pone.0012994","article-title":"Equitoxic doses of 5-Azacytidine and 5-Aza-2\u2032Deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome","volume":"5","author":"Qiu","year":"2010","journal-title":"PLoS ONE"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0179501","article-title":"Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells","author":"Siebenk\u00e4s","year":"2017","journal-title":"PLoS ONE"},{"key":"B46","doi-asserted-by":"publisher","first-page":"12840","DOI":"10.18632\/oncotarget.7326","article-title":"Induction of cancer testis antigen expression in circulating acute myeloid leukemia blasts following hypomethylating agent monotherapy","volume":"7","author":"Srivastava","year":"2016","journal-title":"Oncotarget"},{"key":"B47","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1124\/mol.65.1.18","article-title":"Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine","volume":"65","author":"Karpf","year":"2004","journal-title":"Mol Pharmacol."},{"key":"B48","first-page":"961","article-title":"Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-Aza-2\u2032-deoxycytidine","volume":"62","author":"Liang","year":"2002","journal-title":"Cancer Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/leu.2011.207","article-title":"CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors","volume":"26","author":"Negrotto","year":"2012","journal-title":"Leukemia"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/ng.3889","article-title":"DNMT and HDAC inhibitors induce cryptic transcription start sites encoded in long terminal repeats","volume":"49","author":"Brocks","year":"2017","journal-title":"Nat Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"B52","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","article-title":"DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts","volume":"162","author":"Roulois","year":"2015","journal-title":"Cell"},{"key":"B53","doi-asserted-by":"publisher","first-page":"28812","DOI":"10.18632\/oncotarget.15807","article-title":"Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive\/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease","volume":"8","author":"Tobiasson","year":"2017","journal-title":"Oncotarget"},{"key":"B54","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1172\/JCI67580.miRNA-146a","article-title":"Induction of myelodysplasia by myeloid-derived suppressor cells","volume":"123","author":"Chen","year":"2013","journal-title":"J Clin Invest."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00432-017-2394-6","article-title":"Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells","volume":"143","author":"Zhou","year":"2017","journal-title":"J Cancer Res Clin Oncol."},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1216290","article-title":"Vaccination of stage III\/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope","author":"Baumgaertner","year":"2016","journal-title":"Oncoimmunology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1182\/bloodadvances.2017014175","article-title":"Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia","volume":"2","author":"Maslak","year":"2018","journal-title":"Blood Adv."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1111\/cas.13409","article-title":"Phase 1\/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome","volume":"108","author":"Ueda","year":"2017","journal-title":"Cancer Sci."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/1078-0432.CCR-17-1792","article-title":"NY-ESO-1 vaccination in combination with decitabine induces antigen-specific T-lymphocyte responses in patients with myelodysplastic syndrome","volume":"24","author":"Griffiths","year":"2017","journal-title":"Clin Cancer Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00262-015-1731-3","article-title":"A phase I trial combining decitabine\/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma","volume":"64","author":"Krishnadas","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med."},{"key":"B63","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"B64","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med."},{"key":"B66","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1038\/leu.2016.233","article-title":"The CALR exon 9 mutations are shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms","volume":"30","author":"Holmstrom","year":"2016","journal-title":"Leukemia"},{"key":"B67","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/leu.2016.290","article-title":"The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms","volume":"31","author":"Holmstr\u00f6m","year":"2017","journal-title":"Leukemia"},{"key":"B68","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/leu.2017.214","article-title":"The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy","volume":"32","author":"Holmstr\u00f6m","year":"2018","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","article-title":"Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm","volume":"43","author":"Wang","year":"2016","journal-title":"Leuk Res."},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/SCITRANSLMED.AAM7729","article-title":"Oncogenic JAK2 V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms","volume":"10","author":"Prestipino","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"e1404215","DOI":"10.1080\/2162402X.2017.1404215","article-title":"Frequent adaptive immune responses against arginase-1","volume":"7","author":"Martinenaite","year":"2017","journal-title":"Oncoimmunology"},{"key":"B72","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00281-016-0593-x","article-title":"Anti-regulatory T cells","volume":"39","author":"Andersen","year":"2017","journal-title":"Semin Immunopathol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"e1433521","DOI":"10.1080\/2162402X.2018.1433521","article-title":"Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response","volume":"7","author":"Holmstr\u00f6m","year":"2018","journal-title":"Oncoimmunology"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e1468957","DOI":"10.1080\/2162402X.2018.1468957","article-title":"Spontaneous T-cell responses against Arginase-1 in chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation","volume":"7","author":"J\u00f8rgensen","year":"2018","journal-title":"Oncoimmunology"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 Blockade in Resectable Lung Cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/ehm.12.69","article-title":"Interferon and the treatment of polycythaemia vera, essential thrombocytemia and myelofibrosis","volume":"6","author":"Silver","year":"2013","journal-title":"Exp. Hematol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"e0165336","DOI":"10.1371\/journal.pone.0165336","article-title":"Differential dynamics of CALR mutant allele burden in myeloproliferative neoplasms during interferon alfa treatment","volume":"11","author":"Kj\u00e6r","year":"2016","journal-title":"PLoS ONE"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.leukres.2013.06.012","article-title":"Long term molecular responses in a cohort of Danish patients with essential thrombocythemia, polycythemia vera and myelofibrosis treated with recombinant interferon alpha","volume":"37","author":"Stauffer Larsen","year":"2013","journal-title":"Leuk Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2015-07-659060","article-title":"Clinical and molecular response to interferon- a therapy in essential thrombocythemia patients with CALR mutations","volume":"126","author":"Verger","year":"2015","journal-title":"Blood"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","article-title":"Increase in circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-\u03b1","volume":"118","author":"Riley","year":"2011","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/ejh.12420","article-title":"Expansion of circulating CD56(bright) natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-\u03b1","volume":"94","author":"Riley","year":"2015","journal-title":"Eur J Haematol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/ejh.12687","article-title":"Interferon-\u03b1 induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera","volume":"97","author":"Riley","year":"2016","journal-title":"Eur. J. Haematol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1080\/10428194.2016.1262032","article-title":"The impact of interferon-alpha2 on HLA genes in patients with polycythemia vera and related neoplasms","volume":"58","author":"Skov","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/leu.2015.326","article-title":"Interferon-alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone","volume":"30","author":"Kiladjian","year":"2015","journal-title":"Leukemia"},{"key":"B85","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.18632\/oncotarget.3324","article-title":"Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS \/ AML patients: A rationale for combined targeting of PD-1 and DNA methylation","volume":"6","author":"\u00d8rskov","year":"","journal-title":"Oncotarget"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02264\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T01:37:44Z","timestamp":1571967464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02264\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,1]]},"references-count":87,"alternative-id":["10.3389\/fimmu.2018.02264"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02264","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,1]]},"article-number":"2264"}}